---
title: "Measurement reliability limits functional benchmarks and shifts where variant effect predictors fa"
id: "biorxiv-17-measurement-reliability-bounds-functional-benchmarks-and-relocates-where"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-17-measurement-reliability-bounds-functional-benchmarks-and-relocates-where"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.14.751496v1?rss=1"
published_at: "2026-09-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Measurement reliability limits functional benchmarks and shifts where variant effect predictors fa
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-17-measurement-reliability-bounds-functional-benchmarks-and-relocates-where
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.14.751496v1?rss=1)
- **Published At:** 2026-09-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Variant effect predictors are commonly benchmarked against **multiplexed assays of variant effect (MAVEs)** rather than clinical labels to avoid circularity, but this introduces a constraint: a predictor's correlation with an assay cannot exceed the assay's own reproducibility. - The author evaluated nineteen predictors across sixteen **territories** (strata) drawn from a frozen atlas of 64,178 saturation genome editing variants spanning seven cancer-susceptibility genes. - Using published replicate scores and standard errors, the study estimates each territory's **reliability ceiling** and demonstrates by simulation that correcting for measurement reliability reduces apparent error above a ceiling of ~0.45 and amplifies it below that threshold. - Reliability ceilings vary more across territories than predictors do; applying reliability correction substantially changes the performance map, especially at splice-site extremes. - The pronounced collapse in effect at canonical splice sites is largely an assay characteristic: the median shortfall relative to coding regions narrows from 1.7-fold to 1.4-fold after correction. - This convergence remains when BARD1 or PALB2 are excluded, but inverts when BRCA1 is omitted; the author therefore reports three leave-one-gene-out folds rather than assuming gene independence and notes that the observed frontier parity depends on a single deposit. - True predictor failure is repositioned to intronic positions 11–50 base pairs from exon boundaries; without correction these failures appear more modest. - Across MaveDB deposits, 2,452 of 2,803 score sets have, at the upper bound, the metadata needed for a reliability estimate though only ~10% are discoverable by a conventional column-name search; among 674 human deposits with a computable ceiling, 29.9–51.8% have ceilings below 0.90. - When scored as classifiers against the assays' own functional calls in three genes, predictors separate damaging from tolerated variants better than their raw correlations imply, but none reaches the strongest evidence band at the 95%-specificity operating point. - The author recommends that territory-resolved benchmarks report a per-stratum **reliability estimate**, or state that the assay does not permit one; this approach requires nothing from depositors and, in the upper-bound assessment, applies to most (87%) of MaveDB.
## Clinical Analysis & Structured Key Points
Measurement reliability bounds functional benchmarks and relocates where variant effect prediction fails | bioRxiv Skip to main content New Results Measurement reliability bounds functional benchmarks and relocates where variant effect prediction fails Ningyi Zhang doi: https://doi.org/10.64898/2026.09.14.751496 Ningyi Zhang Department of Biological Sciences, National University of Singapore Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: cliffzhang{at}u.nus.edu Abstract Info/History Metrics Supplementary material Preview PDF Abstract Background. Variant effect predictors are increasingly benchmarked against multiplexed assays of variant effect (MAVEs) rather than clinical labels, which removes label circularity but introduces a new problem: a correlation against a measurement cannot exceed the measurement's own reproducibility, and precision varies sharply across the territories compared. Results. We scored nineteen predictors across sixteen strata of a frozen atlas of 64,178 saturation genome editing variants in seven cancer-susceptibility genes. From published replicate scores and standard errors we estimated each territory's reliability ceiling, and showed by simulation that the correction reduces error above a ceiling of about 0.45 and amplifies it below. Ceilings vary more across territory than predictors do, and correcting for them redraws the map at the splice extremes. The collapse at canonical splice sites is largely a property of the assay: the median shortfall relative to coding narrows from 1.7- to 1.4-fold; this convergence survives dropping BARD1 or PALB2 but inverts when BRCA1 is dropped, so we report all three leave-one-gene-out folds rather than claim gene independence, and the frontier parity rests on one deposit. Genuine failure lies 11-50 bp into the intron, which the uncorrected map presents as modest. Across MaveDB, 2,452 of 2,803 score sets carry, at the upper bound, what a reliability estimate needs, though a conventional column-name search finds only a tenth; among 674 human deposits with a computable ceiling, 29.9-51.8% fall below 0.90. Scored as classification against the assays' own functional calls in three genes, the same predictors separate damaging from tolerated better than their correlations suggest, though none reaches the strongest evidence band at the 95%-specificity operating point. Conclusions. Territory-resolved benchmarks should report a per-stratum reliability estimate, or state that the assay permits none. It asks nothing of depositors and applies today, at the upper bound, to most (87%) of MaveDB. Competing Interest Statement The authors have declared no competing interest. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Posted September 20, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Measurement reliability bounds functional benchmarks and relocates where variant effect prediction fails Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Measurement reliability bounds functional benchmarks and relocates where variant effect prediction fails Ningyi Zhang bioRxiv 2026.09.14.751496; doi: https://doi.org/10.64898/2026.09.14.751496 Share This Article: Copy Citation Tools Measurement reliability bounds functional benchmarks and relocates where variant effect prediction fails Ningyi Zhang bioRxiv 2026.09.14.751496; doi: https://doi.org/10.64898/2026.09.14.751496 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8013) Biochemistry (18739) Bioengineering (14888) Bioinformatics (44428) Biophysics (22601) Cancer Biology (19724) Cell Biology (26902) Clinical Trials (138) Developmental Biology (13966) Ecology (21005) Epidemiology (2067) Evolutionary Biology (25455) Genetics (16167) Genomics (23508) Immunology (18709) Microbiology (42515) Molecular Biology (18060) Neuroscience (93460) Paleontology (700) Pathology (2978) Pharmacology and Toxicology (5095) Physiology (8114) Plant Biology (15999) Scientific Communication and Education (2095) Synthetic Biology (4560) Systems Biology (10235) Zoology (2391)
## Related Clinical Research

- [Investigation finds 20 unnecessary mastectomies at County Durham and Darlington trust](https://medichelpline.com/clinical-feed/bmj-2-mastectomy-scandal-twenty-women-had-unnecessary-procedure-at-trust.md)
- [Interpretable deep learning (TabNet) predicts early immune-related adverse events in hepatocellula](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-development-and-external-validation-of-an-interpretable-deep-learning-model-for.md)
- [EnBCDet: Explainable Contrastive Self-Supervised Model for Malignant Cell Detection in Urine Cytol](https://medichelpline.com/clinical-feed/pubmed-42765133.md) (DOI: 10.1088/2057-1976/aea429)
- [BCLXL blockade as strategy to overcome PARP inhibitor resistance in ovarian cancer](https://medichelpline.com/clinical-feed/pubmed-42764286.md) (DOI: 10.1038/s41392-026-02870-7)
- [Telix to Acquire ITM in $1.65B Radiopharmaceuticals Merger](https://medichelpline.com/clinical-feed/stat-news-8-stat-radiopharma-companies-merge-after-one-receives-surprise-fda-rejection.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.